an article was written about some health care companies that might not do so well in the month of August. These companies include Cardinal Health, Catalyst Pharmaceuticals, and Verona Pharma. People are warning that these companies' stocks may be overbought, which means people might have paid too much for them. Read from source...

1. The author's enthusiasm for stocks that might be considered "overbought" based on the RSI is evident throughout the article, but the criteria for defining "overbought" is not clearly explained. 2. The author provides an overview of Cardinal Health, Catalyst Pharmaceuticals, and Verona Pharma, but the reasons for selecting these specific stocks are not clear. 3. The author fails to address the risks associated with investing in stocks that are considered "overbought" and does not offer any strategies for managing these risks. 4. The article contains several grammatical errors and inconsistent use of punctuation. 5. The article seems to encourage readers to take unnecessary risks, as investing in "overbought" stocks is not advisable without proper risk management strategies. 6. The author appears to have a positive bias towards health care stocks and may not have conducted a comprehensive analysis before selecting the stocks mentioned in the article. 7. The article fails to consider the broader market trends and how these may affect the performance of the selected stocks. 8. The article lacks a clear conclusion and does not offer any actionable advice to readers.

1. Cardinal Health Inc (CAH): With an RSI value of 72.55 and shares gaining 1.9% to close at $102.58 on Tuesday, CAH appears to be on the verge of an overbought situation. However, the company recently posted better-than-expected quarterly results, which indicates a strong operational execution and record financial results. A 9% gain over the past month and a 52-week high of $116.04 also show potential. Despite this, investors should be cautious of the RSI value, as CAH could potentially crash in the short term.

2. Catalyst Pharmaceuticals Inc (CPRX): With an RSI value of 73.73 and shares gaining 1.5% to close at $19.59 on Tuesday, CPRX is also showing signs of being overbought. However, the company reported better-than-expected second-quarter financial results and a successful U.S. commercial launch of AGAMREE, which aligns with its revenue guidance for the year. Despite this, investors should consider the risks of a short-term crash due to the high RSI value.

3. Verona Pharma PLC - ADR (VRNA): With an RSI value of 71.22 and shares gaining 8.3% to close at $26.73 on Tuesday, VRNA is also potentially overbought. However, the company recently posted a narrower-than-expected quarterly loss and its maintenance treatment for chronic obstructive pulmonary disease is now available in the U.S. This shows potential for growth. Despite this, investors should consider the risks of a short-term crash due to the high RSI value.

Investors should consider the risks and potential for short-term crashes due to high RSI values before investing in these stocks. They should also conduct further research and analyze other factors before making any investment decisions.